22
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Extent, impact, and predictors of diagnostic delay in Pompe disease: A combined survey approach to unveil the diagnostic odyssey

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Early diagnosis is of substantial benefit for patients with Pompe disease. Yet underdiagnosing and substantial diagnostic delay are still frequent and the determinants of this are unknown. This study is the first to systematically investigate the diagnostic odyssey in Pompe disease from patients', parents', and physicians' perspectives.

          Methods

          Patients with infantile or late onset Pompe disease, their parents as well as their metabolic experts were invited to fill in respective surveys. The survey addressed perceived disease symptoms at onset and during the course of the disease, specialties of involved physicians, activities of patient‐initiated search for diagnosis and the perceived impact of time to diagnosis on outcome. Results of experts' and patients'/parents' surveys were compared and expressed by descriptive statistics.

          Results and Discussion

          We collected data on 15 males and 17 females including 9 infantile and 23 late onset Pompe patients. All received the correct diagnosis at a metabolic or musculoskeletal expert center. Patients with direct referral to the expert center had the lowest diagnostic delay, while patients who were seen by several physicians, received the correct diagnosis after 44%‐200% longer delay. The proportion of direct referral varied strongly between pediatricians (57%) and other disciplines (18%‐36%).

          Conclusion

          Our study highlights a substantially larger diagnostic delay in Pompe patients that are not directly referred to expert centers for diagnostic work. Our findings may be used to develop more successful strategies for early diagnosis.

          Synopsis

          Diagnostic delay in Pompe disease is substantial particularly in patients that are not directly referred to expert centers for diagnostic workup, so facilitating direct referral may be a new strategy for early diagnosis.

          Related collections

          Most cited references11

          • Record: found
          • Abstract: found
          • Article: not found

          Pompe's disease.

          Pompe's disease, glycogen-storage disease type II, and acid maltase deficiency are alternative names for the same metabolic disorder. It is a pan-ethnic autosomal recessive trait characterised by acid alpha-glucosidase deficiency leading to lysosomal glycogen storage. Pompe's disease is also regarded as a muscular disorder, but the generalised storage of glycogen causes more than mobility and respiratory problems. The clinical spectrum is continuous and broad. First symptoms can present in infants, children, and adults. Cardiac hypertrophy is a key feature of classic infantile Pompe's disease. For a long time, there was no means to stop disease progression, but the approval of enzyme replacement therapy has substantially changed the prospects for patients. With this new development, the disease is now among the small but increasing number of lysosomal storage disorders, for which treatment has become a reality. This review is meant to raise general awareness, to present and discuss the latest insights in disease pathophysiology, and to draw attention to new developments about diagnosis and care. We also discuss the developments that led to the approval of enzyme replacement therapy with recombinant human alpha-glucosidase from Chinese hamster ovary cells (alglucosidase alfa) by the US Food and Drug Administration and European Medicines Agency in 2006, and review clinical practice.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            alpha-Glucosidase deficiency in generalized glycogenstorage disease (Pompe's disease).

            H Hers (1962)
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Consensus treatment recommendations for late-onset Pompe disease.

              Pompe disease is a rare, autosomal recessive disorder caused by deficiency of the glycogen-degrading lysosomal enzyme acid alpha-glucosidase. Late-onset Pompe disease is a multisystem condition, with a heterogeneous clinical presentation that mimics other neuromuscular disorders. Objective is to propose consensus-based treatment and management recommendations for late-onset Pompe disease. A systematic review of the literature by a panel of specialists with expertise in Pompe disease was undertaken. A multidisciplinary team should be involved to properly treat the pulmonary, neuromuscular, orthopedic, and gastrointestinal elements of late-onset Pompe disease. Presymptomatic patients with subtle objective signs of Pompe disease (and patients symptomatic at diagnosis) should begin treatment with enzyme replacement therapy (ERT) immediately; presymptomatic patients without symptoms or signs should be observed without use of ERT. After 1 year of ERT, patients' condition should be reevaluated to determine whether ERT should be continued. Copyright © 2011 Wiley Periodicals, Inc.
                Bookmark

                Author and article information

                Contributors
                florian.lagler@pmu.ac.at
                martina.huemer@lkhb.at
                Journal
                JIMD Rep
                JIMD Rep
                10.1002/(ISSN)2192-8312
                JMD2
                JIMD Reports
                John Wiley & Sons, Inc. (Hoboken, USA )
                2192-8304
                2192-8312
                17 July 2019
                September 2019
                : 49
                : 1 ( doiID: 10.1002/jmd2.v49.1 )
                : 89-95
                Affiliations
                [ 1 ] Institute for Inborn Errors of Metabolism, Paracelsus Medical University Salzburg Austria
                [ 2 ] Department of Paediatrics Paracelsus Medical University Salzburg Austria
                [ 3 ] Division of Metabolism and Children's Research Centre University Children's Hospital Zurich Switzerland
                [ 4 ] Division of Metabolic Diseases (Villa Metabolica) Center for Diseases in Childhood and Adolescence, Mainz Medical University Mainz Germany
                [ 5 ] Department of Neurology Cantonal Hospital St. Gallen Switzerland
                [ 6 ] Department of Neurology, Inselspital University Hospital Bern Switzerland
                [ 7 ] Center of Endocrinology and Metabolism, Rheumatology and Neurology Endokrinologikum Frankfurt Frankfurt a. M. Germany
                [ 8 ] Radiz – Rare Disease Initiative Zürich, Clinical Research Priority Program University of Zürich Zürich Switzerland
                [ 9 ] Department of Paediatrics Landeskrankenhaus Bregenz Austria
                Author notes
                [*] [* ] Correspondence

                Florian B. Lagler, Institute for Inborn Errors of Metabolism and Department of Paediatrics, Paracelsus Medical University, Salzburg, Austria.

                Email: florian.lagler@ 123456pmu.ac.at

                Martina Huemer, Division of Metabolism and Children's Research Centre, University Children's Hospital, Zürich, Switzerland.

                Email: martina.huemer@ 123456lkhb.at

                [†]

                Florian B. Lagler and Martina Huemer contributed equally to this study.

                Author information
                https://orcid.org/0000-0002-1439-6961
                Article
                JMD212062
                10.1002/jmd2.12062
                6718115
                31497486
                c83db2ab-4750-4d86-a6b3-1ca1d75c13d8
                © 2019 The Authors. Journal of Inherited Metabolic Disease published by John Wiley & Sons Ltd on behalf of SSIEM.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 20 February 2019
                : 29 May 2019
                : 03 June 2019
                Page count
                Figures: 3, Tables: 0, Pages: 7, Words: 3690
                Funding
                Funded by: Genzyme a Sanofi Company
                Categories
                Research Report
                Research Reports
                Custom metadata
                2.0
                jmd212062
                September 2019
                Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.8 mode:remove_FC converted:02.09.2019

                pompe disease,diagnostic odyssey,diagnostic delay,expert centers,initial symptoms,patient perspective,survey

                Comments

                Comment on this article